Cytomegalovirus Infection Management

Laboratory Tests

• The most appropriate laboratory tests for diagnosing CMV reactivation are tissue PCR and immunohistochemistry, with tissue PCR having a sensitivity of 65-100% and specificity of 40-100%, and immunohistochemistry having a sensitivity of 93% and specificity of 92-100% 1, 2
• CSF PCR for CMV has a sensitivity of 82-100% and specificity of 86-100% in immunocompromised persons, and should be performed for suspected CNS involvement 3, 4
• The following table summarizes the diagnostic tests for CMV infection:

Diagnostic Considerations for Specific Patient Populations

• For suspected CMV colitis in IBD patients, tissue PCR and immunohistochemistry from colonic biopsies are essential, and multiple biopsies (11-16 samples) from actively inflamed areas are recommended, as blood tests alone are insufficient due to poor sensitivity 1, 5
• In immunocompromised patients, CMV serology interpretation is challenging due to impaired antibody production, and IgG levels alone do not indicate the capacity to mount an effective antibody response against the virus 6
• CMV-seronegative immunocompromised patients should receive CMV-negative or leukocyte-reduced blood products, as recommended by the Centers for Disease Control and Prevention with a high level of evidence 7

Treatment and Management

• Induction with ganciclovir 5 mg/kg IV twice daily for 14-21 days or valganciclovir 900 mg PO twice daily for 21 days, followed by maintenance with valganciclovir 900 mg PO once daily until immune recovery, is recommended by the Centers for Disease Control and Prevention with a high level of evidence 8
• Prophylaxis with valganciclovir 900 mg PO once daily starting within 10 days post-transplant, continuing for 100-200 days depending on transplant type, is suggested by the Infectious Diseases Society of America with a moderate level of evidence 8
• Antiviral therapy should be considered for steroid-refractory IBD patients with CMV colitis, as recommended by the European Crohn's and Colitis Organisation 5

Monitoring and Prevention

• Weekly monitoring with quantitative PCR from day 10 to day 100 post-transplant is recommended for CMV seropositive recipients, as per the National Comprehensive Cancer Network guidelines with a moderate level of evidence 9
• Complete blood count, renal and hepatic function tests should be performed weekly during induction therapy, as suggested by the Infectious Diseases Society of America with a moderate level of evidence 8
• Preemptive treatment based on PCR or antigenemia monitoring is preferred over universal prophylaxis for certain patient groups, according to the CDC with a moderate level of evidence 10

Potential Pitfalls and Complications

• Failing to test for CMV in steroid-refractory inflammatory bowel disease can lead to delayed diagnosis and treatment, as recommended by the European Crohn's and Colitis Organisation with a moderate level of evidence 11
• Delaying treatment in suspected cases of CMV disease in severely immunocompromised patients can lead to poor outcomes, as recommended by the National Comprehensive Cancer Network with a high level of evidence 12
• Discontinuing maintenance therapy prematurely in HIV patients before adequate immune recovery can lead to relapse, as suggested by the Centers for Disease Control and Prevention with a high level of evidence 12